share_log

SVB Leerink Downgrades Global Blood Therapeutics to Market Perform, Announces $68.5 Price Target

Benzinga Real-time News ·  Aug 9, 2022 06:38

SVB Leerink analyst Andrew Berens downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and announces $68.5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment